Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrolizumab versus infliximab in TNF inhibitor-naive ulcerative colitis
NL-OMON47727Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrolizumab arm with Infliximab arm (2 arms). Primary endpoint: Clinical response at Week 10 and clinical remission at Week 54. Started Jul 2015; status: active, not recruiting.
02
Drugs
Etrolizumabinfliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON47727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47727.